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ABSTRACT 18 
 19 
Objective  Benzodiazepines and “Z-drug” GABA-receptor modulators (BDZ) are amongst the most 20 
frequently used drugs in hospitals. Adverse drug events associated with BDZ can be the result of 21 
preventable medication errors related to dosing, drug interactions and comorbidities. The present 22 
study evaluated inpatient use of BDZ and related medication errors and adverse drug events. 23 
Methods  We conducted an observational study within a pharmacoepidemiological database 24 
derived from the clinical information system of a tertiary care hospital. We developed algorithms that 25 
identified dosing errors and interacting comedication for all administered BDZ. Associated adverse 26 
drug events and risk factors were validated in medical records. 27 
Results  Among 53081 patients contributing 495813 patient-days BDZ were administered to 25626 28 
patients (48.3%) on 115150 patient-days (23.2%). We identified 3372 patient-days (2.9%) with 29 
comedication that inhibits BDZ metabolism, and 1197 (1.0%) with lorazepam administration in 30 
severe renal impairment. After validation we classified 134, 56, 12, and 3 cases involving 31 
lorazepam, zolpidem, midazolam and triazolam, respectively, as clinically relevant medication 32 
errors. Among those there were 23 cases with associated adverse drug events, including severe 33 
CNS-depression, falls with subsequent injuries and severe dyspnea. Causality for BDZ was formally 34 
assessed as ‘possible’ or ‘probable’ in 20 of those cases. Four cases with medication errors and 35 
associated severe adverse drug events required administration of the BDZ antagonist flumazenil. 36 
Conclusions  BDZ use was remarkably high in the studied setting, frequently involved potential 37 
medication errors related to dosing, co-medication and comorbidities, and rarely cases with 38 
associated adverse drug events. We propose the implementation of automated medication error 39 
screening and validation for the prevention of BDZ-related adverse drug events.  40 
 3 
INTRODUCTION 41 
 42 
Benzodiazepines and “Z-drug” GABA-receptor modulators (BDZ) are among the most frequently 43 
used drugs worldwide [1-3]. Most BDZ have labeled indications for anxiety and sleeping disorders 44 
[3, 4]. BDZ are also used as add-on therapy for psychiatric disorders, for pre-operative sedation, 45 
and for the prevention and treatment of seizures. They are frequently prescribed in hospitals, 46 
institutions and community dwelling settings and generally considered safe because of their 47 
tolerability and wide therapeutic range [5, 6]. According to their summary of product characteristics 48 
(SPC), BDZ are not destined for long-term use. However, long-term treatment with BDZ is frequent 49 
and may lead to tolerance and addiction [2, 3, 7]. Tolerance and abuse are well known challenges, 50 
for which health authorities and insurances often impose special regulations with regard to BDZ 51 
prescribing, dispensing and compensation [8]. 52 
Severe ADE of BDZ, particularly at higher doses, include musculoskeletal weakness with falls and 53 
subsequent injuries [9-11], respiratory depression [12-15], paradoxical reactions [16-19], or 54 
increased and prolonged CNS depression [4]. If BDZ toxicity is suspected, the antidote flumazenil 55 
can quickly antagonize the effects of BDZ, and it can also be used in emergency care to diagnose 56 
BDZ overdose [4]. Due to altered pharmacokinetics and increased intrinsic sensitivity, BDZ use can 57 
be particularly problematic in elderly and frail patients [20, 21]. Restrictive use of BDZ and low 58 
dosing at treatment initiation is therefore recommended according to their labels and expert 59 
consensus guidelines such as the “Beers” and “Priscus” lists, or the “STOPP” criteria [4, 22-24]. 60 
Some drugs may also inhibit the metabolism of BDZ via cytochrome P450 (CYP) enzymes and 61 
therefore cause relevant pharmacokinetic drug-drug-interactions (DDI) [25]. Concomitant use of 62 
strong CYP inhibitors may lead to five- to tenfold increase in BDZ exposure and consequently to 63 
dose-dependent adverse drug effects (ADE). Furthermore comorbidities such as acute renal 64 
impairment or respiratory disease can render patients more vulnerable to adverse effects of BDZ. 65 
Prevalence of formally inadequate use of BDZ has been studied before [7, 9, 26, 27]. For example 66 
Zint et al. found the concomitant use of BDZ with relevant CYP inhibitors to be associated with an 67 
increased risk of hip fractures in a community dwelling setting [9]. However, there is a paucity of 68 
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data on the clinical relevance and preventability of BDZ-related potential medication errors (ME) in 69 
tertiary care settings. In such a setting patients may frequently be polymorbid and frail, have 70 
additional risk factors for BDZ-induced ADE, and may also be more often exposed to potent CYP 71 
inhibitors as compared to patients in other settings. 72 
In order to analyze and improve drug safety in a tertiary care hospital, we created a local 73 
pharmacoepidemiological database with data extracted from the hospital’s clinical information 74 
system. This setup enables us to perform highly efficient retrospective local evaluations of potential 75 
ME and associated ADE in clinical practice, and subsequently develop recommendations for the 76 
effective prevention of ADE. 77 
The current study aimed to perform such analyses and quantify the following outcomes: 1. BDZ 78 
usage patterns and algorithm-detected potential ME, 2. Validated ME with inappropriate BDZ use in 79 
a patient’s individual clinical context, 3. Associated ADE. 80 
 81 
 82 
METHODS 83 
 84 
Study population, data collection and study design 85 
Selection of the study population and overall study design are presented in Figure 1. We conducted 86 
a retrospective observational study that analyzed BDZ usage patterns, potential ME, and associated 87 
ADE in a tertiary care hospital with about 1000 beds and 40 clinical specialty divisions. The cantonal 88 
ethics committee of Zurich (Kantonale Ethikkommission Zürich, KEK-ZH-Nr. 2015-0268), the 89 
hospital’s medical director and the hospital’s center for clinical research had approved the data 90 
extraction, the setup and analysis of the anonymized and de-identified pharmacoepidemiological 91 
database, and the access to original medical records for our research. Patients that had 92 
disapproved the use of their data for research upon admission were excluded from the validation 93 
procedure with review of original medical records. 94 
 95 
Data Source 96 
 5 
We used our previously described comprehensive pharmacoepidemiological database containing 97 
information on demographics, laboratory results and electronic drug prescriptions for hospitalized 98 
patients of a Swiss tertiary care hospital covering admissions from the calendar years 2011 and 99 
2012 [28]. ICD-10 codes of primary diagnoses were available for the calendar year 2012. For the 100 
validation of potential ME and ADE we had access to and reviewed comprehensive electronic 101 
medical records. 102 
 103 
Prevalence of BDZ use and algorithm-based identification of potential medication errors 104 
We developed and programmed algorithms for the automated detection of patient-days with 105 
potential medication errors. Algorithms were customized and validated separately for each studied 106 
BDZ. Our analyses focused on frequently used BDZ with potentially relevant interactions via CYP 107 
metabolism or with altered pharmacokinetics in renal impairment. Clobazam was not analyzed using 108 
automated algorithms because in the studied setting it is predominantly used for treating post-stroke 109 
epilepsy and delirium, two conditions where doses are individually titrated [4]. In order to identify 110 
BDZ administrations and potentially interacting co-medication we used ATC-codes provided by the 111 
WHO.[29] For each BDZ undergoing CYP-metabolism we established a list of relevant CYP 112 
inhibitors. These were based on the drugs’ summary of product characteristics (SPC) and 113 
comprehensive scientific information sources including specialized drug interaction software and 114 
websites [30-33]. The final lists only included CYP-inhibiting drugs with a strong effect according to 115 
at least one reference. Certain strong CYP 3A4 inhibitors (e.g. clarithromycin) are known to 116 
irreversibly bind and inactivate CYP 3A4 enzymes, which results in reduced metabolic capacity until 117 
they are synthesized de novo [33, 34]. Other strong CYP 3A4 inhibitors do not exhibit such a 118 
mechanism-based effect (e.g. itraconazole), but their metabolites may continue to inhibit CYP 119 
metabolism for some time after cessation [35, 36]. Hence administration of strong CYP 3A4 120 
inhibitors was considered potentially relevant if it occurred on the same day or up to two days prior 121 
to BDZ administration and thus defined our search algorithms for patient-days on which BDZ 122 
administration represented a potential ME. Furthermore, we also identified concomitant use of 123 
multiple BDZ, additional relevant CYP inhibitors of CYP 2C19 or 1A2, and co-medication of opioids 124 
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and muscle relaxants on the same day because those may contribute to BDZ associated ADE [37-125 
39]. 126 
Because severe renal impairment is a formal contraindication to the use of lorazepam according to 127 
the Swiss SPC, we developed an algorithm that identified all patients with lorazepam 128 
administrations and a current eGFR < 30 ml/min. Furthermore, we also identified and validated any 129 
use of the specific BDZ antidote flumazenil as a possible indicator of BDZ-related ME. 130 
 131 
Validation of medication errors 132 
For every hospitalization, during which at least one day with a potential ME was identified using the 133 
algorithms described above, we validated the clinical context of the BDZ administrations. For that 134 
purpose we reviewed the original medical records and compiled the following additional information: 135 
indication, dose and route of administration of any BDZ, concomitant use of opioids and muscle 136 
relaxants, long-term oxygen therapy before and after BDZ administration, alcohol and substance 137 
abuse, relevant severe pulmonary and liver diseases, organ transplantation, renal replacement 138 
therapy, and whether the BDZ was administered in a palliative situation. Finally, we assessed the 139 
clinical relevance of these parameters for each patient’s individual clinical situation and determined 140 
whether BDZ administration was a validated ME, i.e. a more cautious or no use of BDZ with 141 
alternative therapy would have been indicated under the given circumstances (Table 1). 142 
 143 
Table 1: Qualitative impact of patient parameters on validation of ME 144 
 145 
Identification and assessment of adverse drug events 146 
Parameter Impact on assessment of ME 
Palliative situation Benefit outweighs risk, no ME ✖ 
Known BDZ abuse Tolerance of high BDZ dose, no ME ✖ 
Low dose of BDZ ≤ 1/2 of standard dose  ↓ 
≥ 1 other BDZ depending on number & dose  ↗ 
Respiratory insufficiency If severe  ↗ 
Hepatic impairment If severe  ↗ 
Age ≥ 65 & dose If initial dose not reduced  ↗ 
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For all validated ME we reviewed comprehensive original medical records for documented 147 
associated ADE including falls, severe and prolonged CNS depression, respiratory depression, 148 
apnea, paradoxical reactions, hypoxemia and coma. If an associated ADE was documented we 149 
assessed the causal relationship using standardized international WHO/CIOMS causality 150 
assessment criteria [40]. We also assessed whether the associated ADE may have been prevented 151 
if a more cautious BDZ use had been recommended in time to the prescribers - such as an initially 152 
lower BDZ dose, omission of additional BDZ, reducing the amount of possible “on demand” BDZ 153 
prescriptions, or using a different BDZ without relevant CYP metabolism or one that can be used in 154 
renal impairment. 155 
 156 
Data analysis 157 
Data analysis was descriptive with presentation of results in tables as appropriate. Frequencies 158 
were calculated with regard to individual patients, hospitalizations and patient-days. Data 159 
management and analyses were done using STATA Version 13.1 (STATA Corporation, 160 
College Station, TX, USA). 161 
 162 
 163 
RESULTS 164 
 165 
Prevalence of BDZ use 166 
Among a source population of 53081 individual patients contributing 82074 hospitalizations and 167 
495813 patient-days, we identified the study population of all BDZ users. Frequency of BDZ use, 168 
demographics and other characteristics of the study population are presented in Table 2. BDZ were 169 
administered on 23.2% of all patient-days, and at least once in 48.3% of all hospitalized patients 170 
and in 41.0% of all hospitalizations. Mean duration of hospitalization was 10 days (median: 5 days). 171 
Polypharmacy was frequent: on 42.0% of patient-days with any BDZ use 11 or more additional 172 
drugs were administered during hospitalization. 173 
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Most frequently coded primary diagnoses for hospitalizations in 2012 with exposure to BDZ were 174 
“other forms of heart disease” (I30-I52, 4.1%), “benign neoplasms, except benign neuroendocrine 175 
tumors” (D10-D36, 4.1%) and “non-inflammatory disorders of female genital tract” (N80-N98, 3.1%). 176 
While lorazepam was the most frequently administered drug regarding patient-days (36.1%), 177 
midazolam was the most frequently used BDZ regarding individual patients (58.5%) and 178 
hospitalizations (52.1%). Zolpidem and oxazepam were also among the most frequently used BDZ. 179 
The use of some BDZ was marginally low, i.e. the combined use of flurazepam, zopiclone, 180 
flunitrazepam, clorazepate, lormetazepam, nitrazepam, temazepam, prazepam and ketazolam 181 
accounted for only 1.4% of all BDZ administrations. For zolpidem, pharmacokinetics and 182 
pharmacodynamics change with age, and the recommended standard-dose is therefore reduced to 183 
5 mg instead of 10 mg in patients ≥65 years of age. It should only be exceeded if efficacy is 184 
insufficient with 5 mg according to the SPC. Therefore, the age- and dose-distributions for zolpidem 185 
users are of particular interest. A mildly higher proportion of patient-days with zolpidem use 186 
occurred in patients ≥65 years of age compared to all BDZ users (45.8% vs. 41.1%, respectively). 187 
Among all patient-days with zolpidem use the daily dose was at least 10 mg per day in 74.2%, but 188 
for the subpopulation of patients ≥65 years this was almost as high, i.e. 67.4%. This is equivalent to 189 
the impressive absolute number of 10749 days of zolpidem use with a dose ≥10 mg per day in 190 
patients ≥65 years in the studied population over two years. 191 
Administration of two different BDZ at the same day occurred in 7.1% of patient-days, and 211 192 
patients received three or more different BDZ on the same day, with a maximum of 5 different BDZ. 193 
Co-medication with opioids was common (27.2% of patient-days on any BDZ), and on 4.3% of the 194 
studied patient-days two or more opioids were administered concomitantly. The departments with 195 
the highest proportion of BDZ use were the departments of reproductive endocrinology, diagnostic 196 
and interventional radiology, and radio-oncology with BDZ exposure on 45.4%, 34.7% and 33.7% of 197 
patient-days, respectively.  198 
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Table 2: Characteristics of the study population 199 
 patient-days patients hospitalizations 
 n % n % n % 
       
All patients hospitalized in 2011 & 2012 495813  53081  82074  
       
Study population       
Administration of ≥ 1 BDZ 115150 100 25626 100 33661 100 
       
Age       
< 18 1037 0.9 677 2.6 803 2.4 
18 - 44 23831 20.7 7903 30.8 9701 28.8 
45 - 64 42938 37.3 8565 33.4 11632 34.6 
65 - 85 42736 37.1 7608 29.7 10450 31.0 
> 85 4608 4.0 873 3.4 1075 3.2 
       
Sex       
Male 58566 50.9 12860 50.2 17225 51.2 
Female 56584 49.1 12766 49.8 16436 48.8 
       
# of concomitant drugs 
I 
      
1 - 5 24113 20.9 8419 32.9 11430 34.0 
6 - 10 42723 37.1 7530 29.4 10138 30.1 
11 - 20 44861 39.0 6360 24.8 9007 26.8 
≥ 21 3453 3.0 3317 12.9 3086 9.2 
       
Most frequently administered BDZ 
II 
      
Lorazepam 41540 36.1 8704 34.0 10753 31.9 
Zolpidem 34841 30.3 7150 27.9 8873 26.4 
Midazolam 20362 17.7 14993 58.5 17549 52.1 
Oxazepam 11370 9.9 2487 9.7 2929 8.7 
Clobazam 5285 4.6 617 2.4 760 2.3 
Bromazepam 3232 2.8 453 1.8 541 1.6 
Diazepam 1736 1.5 324 1.3 402 1.2 
Alprazolam 1586 1.4 184 0.7 238 0.7 
Clonazepam 1549 1.3 196 0.8 248 0.7 
Triazolam 569 0.5 48 0.2 75 0.2 
       
Administration of ≥ 2 different BDZ       
Use of 2 BDZ 8119 7.1 2887 11.3 3339 9.9 
Use of 3 BDZ 386 0.3 205 0.8 221 5.9 
Use of ≥ 4 BDZ 23 < 0.1 17 0.1 17 < 0.1 
       
Concomitant use of opioids       
Use of 1 opioid 26351 22.9 6505 25.4 7976 23.7 
Use of 2 opioids 4953 4.3 1725 6.7 1978 5.9 
Use of 3 opioids 16 < 0.1 11 < 0.1 12 < 0.1 
       
Concomitant use of muscle 
relaxants 
1860 1.6 322 1.3 1.3 1.1 
       
 200 
I 
Number of concomitant drugs was defined by individual ATC codes. 201 
II
 Considers use of multiple BDZ (benzodiazepines) on same patient-day.  202 
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Drug interactions, renal impairment and potential medication errors 203 
We identified 19 different BDZ that were administered in the studied setting of a tertiary care 204 
hospital. For 9 of those we identified possible clinically relevant CYP-related DDI, and for lorazepam 205 
we identified critical use in severe renal impairment. These patients were further analyzed for 206 
according potential ME and are presented in Table 3. Overall, our algorithms detected potential ME 207 
on 4237 patient-days, occurring during 1066 hospitalizations. This number is equivalent to an 208 
average of 5.8 potential ME regarding BDZ administrations on each calendar day in 2011 and 2012. 209 
Thereof 3372 patient-days with potential ME were due to concomitant administration of BDZ with 210 
strong CYP inhibitors. With the exception of midazolam, BDZ that were used more frequently also 211 
contributed more hospitalizations with potential ME. Most were contributed by zolpidem (2555 212 
patient-days, 7.3% of all zolpidem patient-days) and midazolam (440 patient days, 2.2% of all 213 
midazolam patient-days). Alprazolam contributed only 191 patient-days but was the BDZ with the 214 
highest proportion of potential ME (12.0%). In addition we identified 1197 patient-days with 215 
potentially inadequate administrations of lorazepam in patients with severe renal impairment. 216 
Analysis of flumazenil use identified 15 patient-days (occurring during 13 hospitalizations) with 217 
potential ME related to BDZ use. 218 
Our algorithms detected sporadic patient-days with exposure to numerous studied drugs, e.g. 219 
patients concomitantly receiving 2 BDZ and 2 strong CYP 3A4 inhibitors and 2 opioids and a muscle 220 
relaxant. Other patients received up to 510 mg zolpidem per day, but according to the medical 221 
records very high doses were prescribed intentionally in patients with severe BDZ addiction, and we 222 
therefore did not classify those as ME. 223 
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Table 3: Algorithm-based identification of potential ME 224 
 
Mechanism for potential 
ME 
BDZ total use Potential ME 
patient-days hospitalizations 
patient-
days 
% hospitalizations 
% 
        
Zolpidem 
Co-medication with 
≥ 1 strong 
CYP 3A4 
inhibitor 
 
34841 8873 2555 7.3 493 5.6 
Midazolam
I
 1401 /18989  17549 108 / 332 7.7 / 1.7 192 2.5 
Diazepam 1736 402 106 6.1 15 3.7 
Alprazolam 1586 238 191 12.0 16 6.7 
Triazolam 569 75 9 1.6 3 4.0 
Zopiclone 498 93 9 1.8 2 2.2 
Flunitrazepam 349 75 38 10.9 7 9.3 
Clorazepate 202 31 9 4.5 1 3.2 
Nitrazepam 145 20 0 - 0 - 
Prazepam 48 9 0 - 0 - 
        
Lorazepam Severe renal impairment
II
 41540 10753 1197 2.9 324 3.0 
        
Flumazenil 
BDZ antidote 
(surrogate for BDZ overdose) 
15 13 15 100.0 13 100.0 
        
 225 
I Patient-days with p.o. / i.v. administration; hospitalizations with any i.v. or p.o. midazolam administration 226 
II In order to qualify as potential ME, in addition to eGFR < 30 ml/min, patients hat to EITHER receive lorazepam on ≥ 2 consecutive days OR to 227 
also have had co-administered ≥ 1 additional BDZ 228 
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Validation of medication errors 229 
For 1064 available hospitalizations we assessed the clinical relevance of algorithm-identified 230 
potential ME. After consideration of the patients’ individual clinical situation we classified 205 of 231 
those (19.3%) as validated ME (Table 4). Hospitalizations with potential ME concerning lorazepam 232 
use in severe renal impairment were classified as validated ME in 41.4%. Among potential ME in 233 
hospitalizations with exposure to zolpidem and strong CYP inhibitors, 56 (11.4%) were classified as 234 
validated ME. Most cases were assessed as clinically relevant due to pre-existing respiratory 235 
insufficiency and old age. Among hospitalizations with potential ME concerning midazolam, which is 236 
frequently administered only once before interventions, only 6.3% were confirmed as validated ME. 237 
For three hospitalizations with a potential ME concerning triazolam, all were confirmed as ME while 238 
none out of 15 potential ME with diazepam appeared clinically relevant, mostly because the patients 239 
were known drug addicts. Similarly, the assessment of the clinical context of potential ME with 240 
zopiclone, flunitrazepam and clorazepate did not contribute any validated ME. 241 
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Table 4: Potential- and validated ME and associated ADE 242 
 
hospitalisation
s 
≥ 1 other 
BDZ 
(n) 
≥ 1 
opioid 
(n) 
Indication 
I
 (n)
 
Presence of risk factors (n) 
ADE 
II 
(n)
 
n % 
sleep / anx / inv / 
unkn 
respiratory 
insufficiency 
severe liver 
disease 
Age ≥65 
  
         
Zolpidem potential ME 493 100 
       
 no ME 437 88.6 54 93 432 / 2 / 2 / 1 169 87 109 n.a. 
 validated ME 56 11.4 6 10 55 / 0 / 0 / 1 27 6 38 11 
   validated ME & associated 
ADE 
11 2.2 1 2 11 / 0 / 0 / 0 5 0 5 - 
  
         
Midazolam potential ME 192 100 
       
 no ME 180 93.8 47 51 6 / 24 / 145 / 5 52 18 34 n.a. 
 validated ME 12 6.3 6 6 11 / 0 / 0 / 0 3 1 7 1 
   validated ME & associated 
ADE 
1 0.5 0 1 1 / 0 / 0 / 0 0 0 1 - 
  
         
Triazolam potential ME 3 100 
       
 no ME 0 - - - - - - - n.a. 
 validated ME 3 100.0 1 1 3 / 0 / 0 / 0 1 0 2 1 
   validated ME & associated 
ADE 
1 33.3 0 0 1 / 0 / 0 / 0 1 0 0 - 
          
Lorazepam potential ME 324 100        
 no ME 190 58.6 65 77 99 / 77 / 1 / 13 48 44 106 n.a. 
 validated ME 134 41.4 25 39 100 / 31 / 1 / 2 49 27 82 10 
   validated ME & associated 
ADE 
10 3.1 4 6 7 / 3 / 0 / 0 3 1 8 - 
          
 243 
I Indication: anx = anxiety / inv = pre-invasive / unkn = unkown 244 
II ADE = adverse drug event 245 
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Identification and assessment of adverse drug events 246 
In the 205 hospitalizations where a validated ME had occurred we systematically searched the 247 
original medical records for related ADE. This revealed 23 patients with ADE compatible with 248 
intrinsic effects of BDZ, i.e. falls, prolonged CNS depression and dyspnea (Table 5). According to 249 
WHO/CIOMS causality assessment 15 of the ADE had a “probable”, 5 a “possible” and 3 an 250 
“unlikely” causal relation to the respective BDZ ME. Of the 10 ADE associated with lorazepam, 8 251 
occurred in elderly patients and 7 were found to be preventable if a more cautious use such as no 252 
co-administration of additional BDZ had been respected. Of the 11 ADE associated with zolpidem, 6 253 
occurred in patients ≥65 years and 9 were found to be preventable. According to CIOMS criteria, 254 
the ADE associated with midazolam was assessed as ‘probable’ and preventable. On the other 255 
hand, causality of the ADE with tetrazepam was assessed as ‘possible’ and found not to be 256 
preventable during hospitalization, as BDZ administration and the ADE had actually occurred before 257 
admission. Finally, the identification of all flumazenil administrations in our dataset revealed four 258 
cases of severe ADE resulting from inadequate BDZ administrations. In two of those preventable 259 
ME strong CYP inhibitors had been co-administered with BDZ while in one case lorazepam had 260 
been administered in a patient with severe renal impairment (eGFR of 18 ml/min). Additional 261 
relevant CYP inhibitors and administration of multiple BDZ were also present in all four cases. 262 
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Table 5: Cases with severe ADE 263 
  
total 
number
ADE 
Fall CNS depression  
eGFR
I 
<30 ml/min 
CIOMS Presence of risk factors Preventable 
minor 
injury 
major 
injury
II
 
 
 with respir. 
depression 
 
 
 unlikely possible probable 
respiratory 
insufficiency 
severe liver 
disease 
age ≥65 yes no 
                
Zolpidem 11 5 2 4 2  1 2 1 8 5 - 5 9 2 
Midazolam 1 1 - - -  - - - 1 - - 1 1 - 
Triazolam 1 - 1 - -  - - 1 - 1 - - - 1 
   
 
  
 
  
  
 
  
 
 
Lorazepam 10 4 4 2 2  10 1 3 6 3 1 8 7 3 
   
 
  
 
  
  
 
  
 
 
Flumazenil 4 - 1 3 1  1 - - 4 2 - 2 4 - 
                
 264 
I eGFR = estimated glomerular filtration rate according to CKD-EPI 265 
II Thereof four with subsequent emergency CT scans and one other case with fracture of femur266 
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DISCUSSION 267 
 268 
Our study analyzed BDZ usage patterns, potential medication errors and associated ADE in the 269 
real-life setting of a tertiary care university hospital. In order to perform such analyses we had 270 
previously extracted electronic drug prescriptions, renal function measures and other clinical data 271 
from the database of an existing electronic clinical information system and set up a local 272 
pharmacoepidemiological database. This step is essential for two reasons. First, a rational 273 
allocation of limited available resources to improve hospital drug safety requires systematic 274 
retrospective real-life data on the frequency of preventable ME, and the usually much lower 275 
frequency of resulting severe ADE. Besides, nothing is as convincing to local prescribers and 276 
decision makers as being challenged by opportunities for improvement based on real local ME. 277 
Second, the setup of such a database requires an interface with the local clinical information 278 
system. This is a necessary prerequisite for the development of real-time analyses and alerts that 279 
can be returned through the same interface to local safety experts and prescribers. Only such 280 
systems may eventually offer the necessary efficiency and efficacy in order to have a measurable 281 
impact on patient safety in clinical practice. 282 
 283 
For the currently studied drug class of BDZ we found that their use as well as the risk for drug 284 
interactions was even higher than we had expected. Approximately one out of two patients received 285 
at least once a BDZ during hospitalization. Concomitant exposure to multiple BDZ is rarely justified 286 
but was detected in 7% of patients. And polypharmacy with more than 10 additional concomitant 287 
drugs was present in 42% of patient-days. 288 
At the same time one has to realize that midazolam contributed 17.7% of patient-days with BDZ 289 
use, but midazolam was frequently only administered as a single intravenous dose before smaller 290 
diagnostic or therapeutic procedures. Of note, midazolam drug interactions with CYP inhibitors are 291 
much less important for intravenous as compared to oral administration with pronounced first-pass 292 
metabolism [4, 25]. 293 
 294 
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For each studied BDZ, we applied an individually programmed algorithm that detected patient-days 295 
with potential ME. In addition to the co-administration of strong CYP 3A4 inhibitors, some patients 296 
were exposed concomitantly to inhibitors of CYP 2C19 or CYP 1A2. This may further reduce the 297 
capability to metabolize certain BDZ, (i.e. diazepam, clorazepate and prazepam for 2C19; zolpidem 298 
for 1A2) through the inhibition of a relevant metabolic bypass [3, 32]. Furthermore, the concomitant 299 
use of multiple opioids may further enhance CNS-related ADE of BDZ [37]. Algorithm-based 300 
detection of potential ME was highly efficient, but only clinically relevant prescribing errors should be 301 
considered as true ME and this distinction requires additional manual expert evaluation of individual 302 
patients using weighted information from non-structured data. Adapted dosing (i.e. less than half of 303 
the recommended dose), palliative situations, or known tolerance of high BDZ doses were the most 304 
frequent reasons why potential ME were considered as clinically irrelevant. At the other end of the 305 
spectrum current contraindicated conditions (e.g. severe respiratory failure), co-administration of 306 
multiple additional BDZ and lack of adaptation of the initial dose in elderly patients were the most 307 
frequent reasons why we assessed a potential ME as clinically relevant. Although there is no gold 308 
standard for such an expert validation, we consider it as the best available method, and we have 309 
successfully applied and evaluated it in prospective studies and ward rounds with instant feedback 310 
from the prescribers and subsequent medication changes [41, 42]. 311 
Even a true ME does not always result in a severe ADE, and although the proportion of ME that 312 
actually result in severe ADE is most important from a clinical point of view, this quantitative aspect 313 
is vastly understudied in drug safety research. Therefore, our study systematically searched for and 314 
quantified ADE following all validated ME. As expected, only a small proportion of ME led to severe 315 
ADE, but over a 2-year period we were able to identify the total number of 20 severe ADE following 316 
erroneous administrations of zolpidem, midazolam, triazolam or lorazepam with a formal causality 317 
assessment suggesting a causal role for these BDZ. Prospective screening for the underlying ME 318 
with our automated algorithms would have detected those, and timely alerts could therefore have 319 
effectively prevented them with high efficiency. 320 
Furthermore, we also identified and assessed 15 patient-days with flumazenil administration, which 321 
revealed 4 cases of BDZ related ME that caused severe ADE requiring such antidote treatment. 322 
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Three of those would indeed have been detected in time by our algorithms, which identified co-323 
administration of strong CYP inhibitors in two cases, and relevant renal impairment with an eGFR < 324 
30 ml/min and concomitant exposure to an additional BDZ in another case. Only the remaining 325 
fourth case with flumazenil administration would not have been detected by our algorithms due to 326 
the lack of exposure to any strong CYP inhibitors. It involved the BDZ oxazepam and alprazolam 327 
concomitantly administered with the CYP 3A4 inhibitor fluconazole, which is considered to be only a 328 
moderate CYP 3A4 inhibitor [30, 32]. All four flumazenil cases could likely have been prevented by 329 
either choosing a lower dose of the involved BDZ or by using BDZ which are not affected by CYP 330 
inhibition. Of note, a study in a Brazilian Teaching hospital analyzed the use of flumazenil in patients 331 
exposed to intravenous midazolam and interacting drugs [43]. They identified 23 patients exposed 332 
to clinically significant drug-drug interactions requiring administration of flumazenil during one year. 333 
Most of the cases were related to CNS depressing drugs such as opiates, whereas none were 334 
related to CYP 3A4 inhibitors, for which an interaction is much more pronounced if midazolam is 335 
administered orally. 336 
Although our study focused on identifiable ME with BDZ one should also realize the very high 337 
absolute use of BDZ in the studied setting, and that ADE to BDZ may also occur without preceding 338 
ME. Further interventions should therefore also promote a generally more restrictive use of BZD use 339 
particularly in elderly patients and are supported by expert consensus guidelines such as the 340 
“Beers” and “Priscus” lists, or the “STOPP” criteria [4, 22-24]. 341 
Furthermore, our results showed that compliance with dose-adaptation recommendations for 342 
zolpidem in elderly patients is very low, i.e. two thirds of zolpidem users receive ≥10 mg/day. In 343 
combination of the high prevalence of zolpidem use this resulted in the remarkably high absolute 344 
number of 10749 patient days with ≥10 mg of zolpidem use per day in patients ≥65 years over two 345 
years in a tertiary care hospital. An analysis of ADE resulting from all high zolpidem doses in elderly 346 
patients was beyond the scope of the current study, but our personal experience from safety ward 347 
rounds shows that most prescribers are not aware of recommended dose adaptations for zolpidem 348 
in elderly patients and readily change the dose when this is brought to their attention. 349 
 350 
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In conclusion BDZ use was remarkably high in the studied setting of a tertiary care hospital. Our 351 
algorithms are able to identify potential ME for BDZ prescriptions through an automated analysis of 352 
interacting co-medication and impaired renal function with high efficiency. Although this was done 353 
retrospectively in the current study, our next aim is the implementation of prospective real-time 354 
screening algorithms for ME that issue immediate alerts. We found that about 20% of potential ME 355 
for BDZ prescriptions identified through our automated search algorithms were assessed as 356 
clinically relevant, i.e. BDZ prescriptions should have been changed. This further selection of 357 
clinically relevant ME still requires manual expert evaluation with a review of patients’ clinical 358 
situation and individual risk-benefit evaluation. However, if an automated algorithm performs the 359 
screening it would be an easy task for a trained expert to review the approximately 6 alerts that 360 
would be generated per day and subsequently recommend prescription changes in 1 to 2 patients 361 
per day. Although serious ADE following ME with BDZ are fortunately rare, our findings indicate that 362 
such a system may prevent approximately 10 severe ADE per year in a tertiary care hospital. This 363 
absolute number is clinically relevant and may stand in a favorable relation to the resources that are 364 
required for the maintenance of a semi-automated proactive safety surveillance system. In addition, 365 
automated alerts for dose reduction of zolpidem in elderly patients and a generally more restrictive 366 
use of BZD may also prevent a considerable number of BDZ-related ADE and should be further 367 
investigated in future studies.  368 
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